Literature DB >> 6711425

Effect of amiodarone on serum quinidine and procainamide levels.

A K Saal, J A Werner, H L Greene, G K Sears, E L Graham.   

Abstract

Serum levels of quinidine or procainamide were measured in patients who had amiodarone added to their antiarrhythmic regimen. Dosages of quinidine or procainamide were held constant. Eleven of 11 patients had an increase in the serum quinidine level, and 11 of 12 other patients had an increase in the serum procainamide level. The dose requirement to maintain a stable plasma level of quinidine or procainamide decreased by 37% and 20%, respectively. Clinical toxicity occasionally occurred with the increase in serum levels of quinidine and procainamide, and the dose of these drugs should be decreased when amiodarone is administered concurrently.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6711425     DOI: 10.1016/0002-9149(84)90076-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

Review 1.  Risk-benefit assessment of amiodarone in the treatment of cardiac arrhythmias.

Authors:  P J Counihan; W J McKenna
Journal:  Drug Saf       Date:  1990 Jul-Aug       Impact factor: 5.606

Review 2.  Recent advances in understanding the pharmacology of amiodarone.

Authors:  S Nattel; M Talajic
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

3.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 4.  Pharmacokinetic drug interactions with amiodarone.

Authors:  L J Lesko
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

Review 5.  Adverse effects of amiodarone. Pathogenesis, incidence and management.

Authors:  G V Naccarelli; R L Rinkenberger; A H Dougherty; D M Fitzgerald
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

Review 6.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

7.  Combined anti-arrhythmic therapy with class 1 and class 3 drugs.

Authors:  M A James; P Papouchado; J V Jones
Journal:  Postgrad Med J       Date:  1989-08       Impact factor: 2.401

Review 8.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 9.  New antiarrhythmic drugs.

Authors:  P F Nestico; J Morganroth; L N Horowitz
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

10.  Effect of amiodarone and desethylamiodarone on the pharmacokinetics of antipyrine in the rat.

Authors:  C K Svensson; L L Liu; P W Knowlton
Journal:  Pharm Res       Date:  1987-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.